Innervace, a regenerative medicine startup co-founded by Penn Medicine’s Kacy Cullen, PhD, Associate Professor of neurosurgery and Douglas Smith, MD, Director of Brain Injury and Repair, recently announced the successful close of its $40 million Series A financing round. The company is developing the first implantable biofabricated neural pathway to restore damaged or diseased brain circuitry. The new funding will accelerate efforts to develop Innervace’s lead program, which aims to reconstruct the lost nigrostriatal pathway in patients with Parkinson’s Disease. Innervace’s novel strategy of using certain dopaminergic phenotype cells in combination with a biofabricated scaffold pathway differentiates the company’s products from other cell therapy approaches currently in development for the potential treatment of Parkinson’s Disease. The financing round was led by Deerfield Management with participation from founding investor IP Group, Inc., Penn Medicine, WARF Ventures, and BioAdvance.